Evidence map›Paper›PMID 24443700›Full record

ArticleACS medicinal chemistry letters2013

Discovery of Novel Putative Inhibitors of UDP-GlcNAc 2-Epimerase as Potent Antibacterial Agents.

Yong Xu, Benjamin Brenning, Adrianne Clifford, David Vollmer, Jared Bearss, Carissa Jones, Virgil McCarthy, Chongtie Shi, Bradley Wolfe, Bhasker Aavula and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yong XuAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A.
Benjamin BrenningAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A.
Adrianne CliffordAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A.
David VollmerAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A.
Jared BearssAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A ; Division of Oncology of School of Medicine and Center for Investigational Therapeutics at Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112 U.S.A (Current Address).
Carissa JonesAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A.
Virgil McCarthyAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A.
Chongtie ShiAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A.
Bradley WolfeAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A.
Bhasker AavulaAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A.
Steve WarnerAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A.
David J BearssAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A ; Division of Oncology of School of Medicine and Center for Investigational Therapeutics at Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112 U.S.A (Current Address).
Michael V McCullarAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A.
Raymond SchuchLaboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, NY 10065, U.S.A.
Adam PelzekLaboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, NY 10065, U.S.A.
Shyam S BhaskaranLaboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, NY 10065, U.S.A.
C Erec StebbinsLaboratory of Structural Microbiology, The Rockefeller University, New York, NY, U.S.A.
Allan R GoldbergAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A ; Avacyn Pharmaceuticals, Inc., Teaneck, NJ, U.S.A. (Current Address).
Vincent A FischettiLaboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, NY 10065, U.S.A.
Hariprasad VankayalapatiAstex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568, U.S.A ; Division of Oncology of School of Medicine and Center for Investigational Therapeutics at Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112 U.S.A (Current Address).

Funding

Vaccines and Therapies Against BotulismU54AI057153 · NIAID · UNIVERSITY OF CHICAGO · PI CROSSON, SEAN · 2003 to 2013
$87.6M
Pathogen-specific drug targets for weaponized bacteriaU19AI056510 · NIAID · ROCKEFELLER UNIVERSITY · PI FISCHETTI, VINCENT A. · 2003 to 2007
$6.2M
Isolaton of new phage enzymes to kill B. anthracisR01AI057472 · NIAID · ROCKEFELLER UNIVERSITY · PI FISCHETTI, VINCENT A. · 2004 to 2014
$3.9M
NIAID NIH HHS R01 AI057472NIAID NIH HHS U19 AI056510NIAID NIH HHS U54 AI057153
6 · The paper itself

Abstract

We present the discovery and optimization of a novel series of inhibitors of bacterial UDP-N-acetylglucosamine 2-epimerase (called 2-epimerase in this paper). Starting from virtual screening hits, the activity of various inhibitory molecules was optimized using a combination of structure-based and rational design approaches. We successfully designed and identified a 2-epimerase inhibitor (compound

Indexed as

2-epimerase inhibitorantibacterial agentantibiotic-resistant pathogensGram-positive bacteriastereo-isomers

Identifiers

PMID24443700
PMCPMC3890692

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.